Benzinga | Nov 29, 2021 06:32AM EST

NRx Pharmaceuticals Identifies Significantly Higher Likelihood Of Surviving And Recovering From Critical COVID-19 In ZYESAMI Treated Patients Previously Administered Remdesivir

* Analysis was conducted in the subgroup of ZYESAMI- and placebo-treated patients who were previously treated with remdesivir in the COVID-AIV trial representing approximately 70 percent of the study population

* Analysis was conducted in response to US Food and Drug Administration (FDA) request for additional clinical data on effect of ZYESAMI compared to currently-approved therapy including remdesivir

* NRx to submit new analysis and safety data to the FDA in support of Emergency Use Authorization and Breakthrough Therapy Designation Requests

* US National Institutes of Health-sponsored trial to compare effects of ZYESAMI and remdesivir individually and in combination continues to enroll patients